Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Draft Guidance on Biosimilar Interchangeability Sets High Standard

XTALKS VITALS NEWS

FDA

According to the regulatory agency, biosimilars will need to demonstrate the same clinical results as branded biologics for all approved indications, in order to be considered interchangeable.

Share this!

January 20, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has released some much-anticipated draft guidance on biosimilar interchangeability with its reference product. According to the regulatory agency, biosimilars will need to demonstrate the same clinical results as branded biologics for all approved indications, in order to be considered interchangeable.

This new regulatory framework sets the bar high for makers of biosimilars. In the US, only four biosimilars have been approved to-date, none of which are considered to be interchangeable with their reference product.



Right now, biosimilars need to demonstrate a high degree of similarity to its branded biologic counterpart in order to gain FDA approval. Drugmakers must show that the safety, purity and potency of a biosimilar match that of its reference product.

Unlike generic drugs however, biosimilars are not chemically identical to biologics, which is the reason why prescribers and pharmacists are unable to automatically substitute one for the other. To achieve interchangeable status, drugmakers will have to conduct trials aimed at determining whether switching from a biologic to a biosimilar poses any risk to the patient.

According to the guidance, post-marketing studies for already-approved biologics will not be sufficient to support an application for interchangeability. The FDA will be accepting comments on their draft guidance until March 20, 2017, at which time they will begin to compose their final guidance.

Sandoz’s biosimilar of Amgen's Neupogen (filgrastim) became the first biosimilar to be approved in the US in 2015. Since then, Sandoz has been granted another biosimilar approval, joining Hospira and Amgen’ approved biosimilars.


Keywords: Biosimilar, Biologic, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.